期刊
DIABETES THERAPY
卷 9, 期 5, 页码 2107-2116出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s13300-018-0480-7
关键词
Acute myocardial infarction; Cardiac sympathetic activity; Empagliflozin; sodium glucose cotransporter 2 (SGLT2) inhibitor; Type 2 diabetes mellitus (T2DM)
资金
- Nippon Boehringer Ingelheim
- Eli Lilly and Co.
Protection from lethal ventricular arrhythmias leading to sudden cardiac death is one of the most important problems after myocardial infarction. Cardiac sympathetic hyperactivity is related to poor prognosis and fatal arrhythmias and can be non-invasively assessed with heart rate variability, heart rate turbulence, T-wave alternans, late potentials, and I-123-meta-iodobenzylguanide (I-123-MIBG) scintigraphy. Sodium glucose cotransporter 2 (SGLT2) inhibitors potentially reduce sympathetic nervous system activity that is augmented in part due to the stimulatory effect of hyperglycemia. The EMBODY trial is designed to determine whether the suppression of cardiac sympathetic activity induced by the SGLT2 inhibitor is accompanied by protection against adverse cardiovascular outcomes. The EMBODY trial is a prospective, multicenter, randomized, double-blind, placebo-controlled trial in patients with acute MI and type 2 diabetes in Japan. A total of 98 patients will be randomized (1:1) to receive once-daily placebo or empagliflozin, an SGLT2 inhibitor, 10 mg. The primary end point is the change from baseline to 24 weeks in heart rate variability. Secondary end points include the change from baseline for other sudden cardiac death surrogate-markers such as heart rate turbulence, T-wave alternans, late potentials, and I-123-MIBG scintigraphy imaging. Adverse effects will be evaluated throughout the trial period. The EMBODY trial will evaluate the potential cardioprotective effect of empagliflozin and will provide additional important new data regarding its preventative effects on sudden cardiac death.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据